In a few months, member states of the World Trade Organization (WTO) will decide whether to expand the TRIPS waiver to include COVID-19 therapeutics and diagnostics. Colorado BioScience Association is continuing to monitor and speak out against the Trade-Relations Aspects of Intellectual Property Rights (TRIPS) waiver, due to the harmful precedent set by waiving intellectual property (IP) protections for the life sciences sector.
Intellectual property is the foundation of our sector. IP protections are essential to the technology transfer process in life sciences that leads from lab invention to life-saving commercial products.
CBSA opposes the TRIPS waiver and any form of expansion to COVID-19 therapeutics or diagnostics. Expanding the waiver would be ineffective and counterproductive in accelerating the global response to the pandemic.
Details on the Current Situation:
During the World Trade Organization (WTO) 12th Ministerial Conference in June 2022, WTO Member States agreed on a decision to…
Click here to view original post
